Spring 2010 meeting of the NORD Corporate Council

The Spring 2010 meeting of the NORD Corporate Council was held on Tuesday, May 18, at The Liaison Capitol Hill in Washington, DC. Senior executives from more than 70 leading companies and organizations participated in the day-long event. Discussion topics ranged from biomedical research and regulatory issues with leading officials from the National Institutes of Health and the Food and Drug Administration -- to the analysis and implementation of health care reform with some of the nation's top health policy experts.

For more information about the Council or the Spring 2010 meeting, please contact Michael Langan, Vice President of Industry Relations at mlangan@rarediseases.org

• NORD Intro Slides
  Peter L. Saltonstall
  President and CEO
  National Organization for Rare Disorders (NORD)
  
  
• Orphan Products Update from FDA
  Timothy Cote, MD, MPH
  Director, Office of Orphan Products Development
  U.S. Food and Drug Administration
  
  
• A New Focus on Rare Diseases at CDER
  Anne Pariser, MD
  Associate Director for Rare Diseases, Office of New Drugs
  Center for Drug Evaluation and Research, FDA
  
  
• Center for Orphan Drug Research, University of Minnesota
  James Cloyd, PharmD
  Director and Professor, Orphan Drug Development
  
  
• NORD Focus Groups on Orphan Product Development
  Noah Pines
  President, Gen Inc.
  
  
• Compassionate Allowances for Rare Disease Patients
  Nancy Schoenberg
  Director, Office of Compassionate Allowances & Disability Outreach
  U.S. Social Security Administration
  
  
• Updates from NORD
  Diane Dorman
  Vice President, Public Policy
  
  Mary Dunkle
  Vice President, Communications
  
  Maria Hardin
  Vice President, Patient Services
  
  
• Medunik Canada
  Eric Gervais
  Executive Vice President, Medunik Canada
  
  
• Special Address from EURORDIS
  Yann Le Cam
  CEO, European Organization for Rare Diseases (EURORDIS)